Pravin Kendrekar

Central University of TechnologySouth Africa

Dr. Pravin is a Researcher in the Department of Health Sciences, Faculty of Health and Environmental Sciences, Central University of Technology, Bloemfontein, Free State, South Africa. Dr. Pravin completed his M.Sc. in organic chemistry, and a PhD in organic synthesis at Nagaoka University of technology, Japan. During his doctoral studies he published high impact-factor journals and presented at various conferences in USA, Mexico, China, Indonesia and also including the Japanese Chemical Society. After his doctoral studies he worked as postdoctoral research associate at the Ben-Gurion University of the Negev, Israel. (2007-2009) and then moved to the University of the free state, Bloemfontein South Africa as a visiting scholar/ Postdoctoral researcher (2010-2016). Dr. Pravin is busy with established organic synthesis lab at CUT, Currently; Dr. Pravin holds a major research grant from Technology and Innovation Agency (TIA), South Africa for the development on novel anti-malaria drugs with the collaboration from the scientist from UK, Brazil, India and Thailand. CUT-UFS joint collaboration funding for the 2 different projects. For the drug development of Anti-Cancer and Anti-Fungal. He is busy with the supervisor of 1 PhD, 10 Master Students and 4 Honors/Btech, Dr. Pravin research is focused on Novel drug discovery and development of Anti-Cancer, TB and Malaria drugs development along with the novel drug development using GCPR in collaboration with Canada. We are having the collaboration for the different projects with world well known Prof. from India, Australia, UK, Japan, Russia, China, Canada, Brazil, Singapore and Thailand. Development of new, effective, safe and affordable tuberculosis (TB) drugs has been identified as an important priority for global TB control. There is now recognition that new drugs to treat TB are urgently required, specifically for use in shorter treatment regimens than are possible with the current agents and which can be employed to treat multidrug-resistant and latent disease. A variety of new initiatives have been created to tackle these objectives, the most recent of which is the establishment of the so-called Global Alliance for TB Drug Development. The Alliance, a public/private partnership in which WHO is a partner, is a not-for-profit venture that will accelerate the discovery and development of new drugs to fight TB using a virtual operating model to outsource projects. A survey in 2016, there were over 10.4 million TB cases worldwide and over 1.8 million deaths attributed to the disease. Nearly 4% of all new TB cases in 2010 were multi-drug resistant (MDR). The current first line drugs for TB (isoniazid, rifampicin, pyrazinamide (PZA) and ethambutol) were discovered decades ago and are increasingly becoming less useful due to emerging resistance and synergistic interactions with HIV AIDS patients. Furthermore, effective use of these drugs require months of combination therapy, leading to issues with compliance and significant side effects. Over the past ten years there has been a major investment by scientists from both academia and pharmaceutical companies into TB drug discovery and development. High-throughput screening (HTS) has become an integral part of pharmaceutical research and fueled drug discovery projects. Drug discovery screens can be either target or cell based/phenotypic. Each has advantages and disadvantages. The power of a target based strategy includes the ability to apply molecular and chemical knowledge to investigate a specific molecular hypothesis and ability to perform HTS against the target. The main limitation is that the molecular hypothesis or target may not be relevant in the disease pathogenesis setting, thus placing a major emphasis on target validation. In contrast, the strength of a phenotypic approach is that the assay does not require knowledge of molecular mechanism of action; however in vitro HTS growth conditions should mimic disease settings. The main drawback of this approach is the challenge in optimizing hits with multi-parametric cell based activity. The advantage of a phenotypic screen is the possibility to find NCEs that inhibit new target/s or pathway/s, and the potential to find pro-drugs and other complex mechanisms of action. All currently used antibiotics were discovered using cell based phenotypic screening, highlighting the value of this approach. It has been estimated by WHO that if the condition remains the same, 30 million people will be infected by M. tuberculosis between the years 2000 and 2020. Thus, there is an urgent need to discover new TB drugs. For Anti-Cancer drug development (Breast-Cancer): The Main Aim of the project to find the novel drug or inhibitors which can be used to stop proliferation and also discover methods that can used to overcome the anti-cancer drug resistance in the form of RB1 mutations and also CDK4\\6 phosphorylation and thus finding new methods to try and develop a drug that overcomes the resistance and patients don’t relapse after taking the molecule for receptor positive breast cancer. I am the member of Indian Chemical Society, Japans Chemical Society and I was regularly reviving the NRF (Master, PhD and PDF funding application, for Y-rated Researcher and Thuthuka Health and Medical Science for Health Sciences along with L’Oréal-UNESCO for Women in Science for South East Africa Funding applications. Funding applications also the reviewer for ACS Omega and one of advisory board member in World Journal of Pharmaceutical Research.

1chapters authored